Open AccessHepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus–HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation
Author(s) -
Donald D. Anthony,
Mark S. Sulkowski,
Laura Smeaton,
Sofi Damjanovska,
Carey L. Shive,
Corinne Kowal,
Daniel E. Cohen,
Debika Bhattacharya,
Beverly Alston-Smith,
Ashwin Balagopal,
David L. Wyles
Publication year - 2020
Publication title -
the journal of infectious diseases (online. university of chicago press)/the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jiaa254
Subject(s) - ombitasvir , paritaprevir , dasabuvir , coinfection , ritonavir , hepatitis c virus , medicine , hepatitis c , virology , immunology , viral load , ribavirin , virus , antiretroviral therapy
Hepatitis C virus (HCV) direct-acting antivirals are highly effective. Less is known about changes in markers of immune activation in persons with human immunodeficiency virus (HIV) in whom a sustained virologic response (SVR) is achieved.